DNA-Pol Inhibitors: A Promising Strategy for Cancer Treatment

Target Name: DNA-Directed DNA Polymerase Complex

NCBI ID: P16165

DNA-Directed DNA Polymerase Complex

Other Name(s): DNA nucleotidyltransferase (DNA-directed) | Deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (DNA-directed) | DNA-dependent DNA polymerase

DNA-Pol Inhibitors: A Promising Strategy for Cancer Treatment

DNA-Directed DNA Polymerase Complex (DNA nucleotidyltransferase (DNA-directed), also known as DNA-pol) is a enzyme that plays a crucial role in the replication and repair of DNA in living organisms. It is a complex protein that consists of multiple subunits that are responsible for moving nucleotides along the DNA double helix in the direction of the replication strand. DNA-pol is essential for the efficient and accurate replication of genetic information in eukaryotic cells.

One of the unique features of DNA-pol is its ability to synthesize new DNA strands in the 5' to 3' direction, which is in opposite direction of the standard 5' to 3' direction of DNA replication. This property is critical for the efficient repair of DNA damage and for the development of genetic mutations.

DNA-pol has been identified as a potential drug target in the field of cancer. Several studies have shown that DNA-pol has altered levels or functions in various types of cancer, including breast, ovarian, and colorectal cancers. Alterations in DNA-pol levels or functions have been associated with the development of these cancers, and targeting DNA-pol with drugs or other therapeutic agents may be a promising strategy for cancer treatment.

One of the key targets of DNA-pol inhibitors is the ability to inhibit the activity of DNA-pol in the 5' to 3' direction. This can be achieved by inhibiting the activity of the enzyme either partially or completely. There are several different strategies that have been used to achieve this goal, including the use of small molecules, antibodies, and RNA-based inhibitors.

One of the most promising strategies for targeting DNA-pol is the use of small molecules. Small molecules have been shown to be effective in inhibiting the activity of DNA-pol, and many of these compounds have been identified as potential drug targets for cancer. For example, a study by the drug development company ImClone has shown that a small molecule called DM1 has the potential to be a useful treatment for breast cancer by inhibiting the activity of DNA-pol in the 5' to 3' direction.

Another approach to targeting DNA-pol is the use of antibodies. Antibodies are proteins that are produced by the immune system to help identify and neutralize foreign substances like viruses or cancer cells. By using antibodies to target DNA-pol, researchers have been able to block its activity in the laboratory and show that this strategy has the potential to be a useful cancer therapeutic.

In addition to small molecules and antibodies, researchers have also been interested in using RNA-based inhibitors to target DNA-pol. These compounds work by binding to specific regions of DNA-pol and inhibiting its activity. RNA-based inhibitors have the advantage of being highly specific and can be designed to target DNA-pol activity in a variety of cell types.

While the use of DNA-pol inhibitors is still in the early stages of research, it has the potential to be a powerful tool for the treatment of cancer. By inhibiting the activity of DNA-pol, researchers can reduce the number of DNA replications that occur during the replication process, which can lead to the formation of DNA damage sites that can be repaired by the cell's repair machinery. This can result in the inhibition of the growth and spread of cancer cells, leading to a reduction in the overall risk of cancer recurrence.

In addition to its potential as a cancer therapeutic, DNA-pol has also been identified as a potential biomarker. The ability of DNA-pol to synthesize new DNA strands in the 5' to 3' direction makes it an attractive candidate for use as a marker for the presence of DNA damage in cells. This can be useful for the development of diagnostic tests for cancer, as well as for monitoring the effectiveness of cancer treatments.

Overall, DNA-Directed DNA Polymerase Complex (DNA nucleotidyltransferase (DNA-directed

Protein Name: DNA-Directed DNA Polymerase Complex

The "DNA-Directed DNA Polymerase Complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNA-Directed DNA Polymerase Complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets